Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Search Results

Refine Your Search

By Sector
Sort by: Date|Relevance

Buzz on the Bullboards: Has COVID’s Storm Passed, or is it the Eye of the Hurricane?

(Image via the National Association of Insurance Commissioners.) With headlines dominated by COVID-19 and one-million-plus jobless claims, the threat of hurricane (now tropical storm) Laura had almost come and gone without much international attention. Its path a...
Stockhouse Editorial | September 9, 2020 |

Biopharma's Technology Could Render Drug Suitable for COVID-19 Treatment

How this could be achieved using the proprietary platform of TFF Pharmaceuticals and why it could work are discussed in a ROTH Capital Partners report. In an April 7 research note, ROTH Capital Partners analyst Jonathan Aschoff discussed the potential of app...
Streetwise Reports | April 9, 2020 |

NervGen Pharma: A “Blockbuster Drug” in the Making?

It has the potential to be one of the most disruptive pharmaceutical drug therapies of the modern era, especially for treating Alzheimer’s disease. And that gives it considerable “blockbuster drug” potential – a tantalising opportunity tha...
Marc Davis | June 25, 2021 |

Why This Well-Timed Strategy is Forcing Them to Re-evaluate a Junior Oil Play in Texas

By Prodigy NewsG2 Energy Corp. is a Canadian, publicly-traded company (CSE:GTOO,OTCQB:GTGEF, FKN:UD9) focused on identifying and developing OVERLOOKED opportunities in the energy sector.The...
Research | July 14, 2022 |

Buzz on the Bullboards: How Markets Carved Out Gains During COVID & Winter Storms

(Image via Extreme Vehicle Battery Technologies Corp.) It is only the end of the second month of the year, but what a year it has been for North American stock markets. The Toronto Stock Exchange and NASDAQ have been especially impacted by the performance of tech st...
Stockhouse Editorial | February 24, 2021 |

Cracking the Code to Society’s Most Feared Disease

Even more so than cancer, it’s the one disease that we all fear the most. The thought of falling prey to Alzheimer’s disease and to the inevitable desecration of our mind is something that makes even the bravest among us shudder. ...
Marc Davis | February 7, 2020 |

Plus Therapeutics Shares Trade Higher on Q3 Earnings and Business Restructuring

Plus Therapeutics shares opened 25% higher today after the firm reported Q3/19 financial and business results. In the most recent quarter, the company completed the change of its name, relocated its headquarters to Austin, and raised $15 million for R&D and working capital. ...
Streetwise Reports | November 18, 2019 |

A psychedelic renaissance

Fifty-three years after LSD was banned by the FDA, psychedelic drugs are making a comeback. Only instead of being the pills, mushrooms and acid tabs that helped college students to “turn on, tune in, drop out” Timothy Leary-style, today’...
Richard (Rick) Mills | December 3, 2019 |

Texas deal shows shift of gas producers to oil investment

SandRidge Energy ’s ( NYSE: SD , Stock Forum ) recent agreement to acquire Arena Resources ( NYSE: ARD , Stock Forum ), a producer of conventional oil in West Texas, for $1.6 billion is the latest example of natural gas companies seeking to balance their...
Darrell Delamaide | October 28, 2012 |

Novamind’s Trial Site for Merck Another Example Of Its Leadership in Mental Health

Novamind’s clinics and clinical research capabilities are already well established to bring alternative mental health therapies, including psychedelic medicine, to market. One of the world’s largest pharmaceutical companies has selected ...
Featured Submission | March 24, 2021 |
1 2 3 4 5 6 7 8 9 10 ...